AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01537705
Drug: Neuron012703 (Medical Food)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 capsules twice daily for sixty days.
Trial: NCT01318460
Drug: Placebo infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twenty-four hour administration of placebo
Trial: NCT04085289
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered SC
Trial: NCT01364844
Drug: DS-7423
RxNorm normalized name: Uretron DS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule 1mg, 8mg, 48mg, and 80mg strengths administered once daily
Trial: NCT00176917
Drug: Busulfan, Cyclophosphamide, ATG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prior to transplantation, subjects will receive BUSULFAN intravenously (IV) via the Hickman line twice daily for 4 days, CYCLOPHOSPHAMIDE intravenously via the Hickman line once a day for 4 days, and ANTI-THYMOCYTE GLOBULIN IV via the Hickman line twice daily for three days before the transplant. These three drugs are being given to help the new marrow take and grow. METHYLPREDNISOLONE will be given as a pre-medication for the ATG.
Trial: NCT03849508
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug: Norepinephrine Norepinephrine tartrate variable infusion with a starting rate of 0,1μg/kg/min (equivalent to norepinephrine base of 0.05 μg /Kg/min).~Other name: Noradrenaline~Drug: Hyperbaric Bupivacaine will be injected in the subarachnoid space with a dose of 8 to 12 mg adjusted according to height~Drug: Sufentanil will be injected in the subarachnoid space with a dose of 2,5μg~Drug: Morphine will be injected in the subarachnoid space with a dose of 100 μg
Trial: NCT02577718
Drug: Nitroglycerin-citrate-ethanol (NiCE)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lock solution instilled in catheter lumens for 2 hours then flushed. Administration for up to 30 days, daily as in-patient or once weekly as out-patient
Trial: NCT02812862
Drug: Spiolto® Respimat® (Tiotropium / Olodaterol)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LABA/ LAMA combination therapy:~A combination of two bronchodilators acting on two separate pharmacological targets - one ß-agonist and one anti-muscarinergic agent.
Trial: NCT02561832
Drug: Anthracycline
RxNorm normalized name: Anthracycline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Trial: NCT02561832
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: The choice of anthracycline and cyclophosphamide (AC) regimen in Part B will be up to local Investigator following international guidelines
Trial: NCT00499083
Drug: aromatase inhibition therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant hormone therapy for patients having tumors with estrogen and/or progesterone receptors. Premenopausal patients will be treated with tamoxifen. Post or perimenopausal women may receive tamoxifen or an aromatase inhibitor (AI) or those drugs in sequence as determined by the treating oncologist. Hormone therapy will be given for at least 5 years.
Trial: NCT00499083
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 IV day 1 every 2 weeks for 4 cycles
Trial: NCT00499083
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 IV day 1 every 2 weeks for 4 cycles
Trial: NCT02567578
Drug: YH12852 0.1 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02567578
Drug: YH12852 0.25 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02567578
Drug: YH12852 0.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02567578
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02222948
Drug: Placebo (for Vatelizumab)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form: solution for infusion~Route of administration: intravenous
Trial: NCT04238364
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching Placebo Tablet(s)
Trial: NCT00252668
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02283827
Drug: BIA 2-093
RxNorm normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02283827
Drug: Phenytoin
RxNorm normalized name: Phenytoin
DrugBank: Phenytoin (DB00252)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01680471
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will be injected intravenous normal saline five minutes before the end of surgery.~If emergence agitation is severe, the patients will be treated by psychological support from the parents or nurse and intravenous fentanyl 1㎍/kg.
Trial: NCT01174719
Drug: volume replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyethylstarch up to 50mL/kg/24 hrs
Trial: NCT01174719
Drug: Humanalbumin 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Humanalbumin 5% up to 50 mL/kg/24 hours
Trial: NCT01174719
Drug: volume replacement
FDA approved: no
EMA approved: no
PMDA approved: no
Description: up 10 50mL/kg/24 hours
Trial: NCT00663091
Drug: Bacteriophage
RxNorm normalized name: bacteriophages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Trial: NCT00663091
Drug: WPP-201 Bacteriophage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Trial: NCT00663091
Drug: Bacteriophages
RxNorm normalized name: bacteriophages
FDA approved: no
EMA approved: no
PMDA approved: no
Description: WPP-201 is a pH neutral, polyvalent phage preparation, which contains 8 bacteriophages (component bacteriophages or component phages) lytic for P. aeruginosa, S. aureus, and E. coli (Table 1). The cocktail contains a concentration of approximately 1 x 109 PFU/ml of each of the component monophages. The phage component of WPP-201 is roughly estimated to be £ 0.5 ppm by weight and the remainder is phosphate-buffered saline containing \< 1,000 ppm total organic carbon from the growth medium and biomass. All phages contained in the preparation have been originally isolated from the environment, and they have not been genetically manipulated in any way (i.e., the preparation is 100% natural). WPP-201 contains no preservatives and antioxidants.
Trial: NCT01855594
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, 6 week course of oral administration
Trial: NCT00060840
Drug: Nitric Oxide
RxNorm normalized name: Nitric Oxide
DrugBank: Nitric Oxide (DB00435)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 40 ppm of Nitric Oxide continuously administered for 48 hours
Trial: NCT00976560
Drug: GW856553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Wet Granulated, film coated white, 9mm round, biconvex, plain faced tablets, containing 7.5 mg of GW856553
Trial: NCT04623632
Drug: Transversus abdominus plane placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: injection of 40 ml of normal saline in the transversus abdominus plane
Trial: NCT04472832
Drug: Placebo for Treatment A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 tablets matched to mitapivat tablet
Trial: NCT04472832
Drug: Placebo for Treatment B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets matched to mitapivat tablet
Trial: NCT04472832
Drug: Placebo for Treatment C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 tablets matched to mitapivat tablet
Trial: NCT00151775
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cohorts A, B, C: placebo, once daily
Trial: NCT01301027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 pill a day for 26 weeks
Trial: NCT00080236
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00074490
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin:10 mg/m(2)/day continuous intravenous (CIV), days 1-4.
Trial: NCT00074490
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide, 300 mg/m(2)/day intravenous (IV), days -6 to -3.
Trial: NCT02389621
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets for oral administration
Trial: NCT03039686
Drug: RO7239361
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take RO7239361 subcutaneously on specified days over a 48 week blinded period
Trial: NCT00997308
Drug: AZD1446
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Solution, oral, for 4 weeks
Trial: NCT00997308
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03039686
Drug: Placebo for RO7239361
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Take placebo subcutaneously on specified days over a 48 week blinded period
Trial: NCT00067002
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg/kg by vein on Day -6.
Trial: NCT00717808
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The patient will receive the placebo capsule twice a day whilst receiving their weekly dose of methotrexate
Trial: NCT00002630
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03614156
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (prefilled syringe, weekly IV administration)
Trial: NCT03980704
Drug: resource protein
RxNorm normalized name: Resource Protein Powder
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of oral high-protein oral supplement
Trial: NCT02407600
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01587924
Drug: GSK1278863
FDA approved: no
EMA approved: no
PMDA approved: no
Description: tablet
Trial: NCT01286051
Drug: Follistim administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: adminstation of FSH for ovulation induction
Trial: NCT02447302
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02653599
Drug: TTP273
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02653599
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002618
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002618
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00002618
Drug: mercaptopurine
RxNorm normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00002618
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03783715
Drug: Ketoprofen
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ketoprofen 200 mg ER, taken orally, once a day for 6 months. If medication, if obtained from a compound pharmacy, dose will be 210 mg ER, taken orally once a day for 6 months.
Trial: NCT00870519
Drug: I-123-MNI-168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Trial: NCT00870519
Drug: 123-I MNI-168
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 mCi (not \>10% of 5 mCi limit) of 123-I MNI-168 followed by serial SPECT imaging.
Trial: NCT02052999
Drug: Rozex gel 0.75%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received topical Rozex gel 0.75% twice daily for 8 weeks
Trial: NCT03200080
Drug: Placebo oral tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2, 4, 6 or 8 Tozadenant matching placebo tablets
Trial: NCT02452008
Drug: LY2157299
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of LY2157299 is administered orally twice a day on days 1-14 of each cycle.
Trial: NCT03200080
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 or 4 capsules, each containing d-amphetamine matching over-encapsulated PLACEBO 200 mg lactose tablet
Trial: NCT02665832
Drug: DWJ1351
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02665832
Drug: Co-administration of Sevikar (Olmesartan/Amlodipine) and Crestor (Rosuvastatin)
RxNorm normalized name: rosuvastatin Oral Tablet [Crestor]
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03500224
Drug: [14C]-TAK-954
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\]-TAK-954 intravenous infusion.
Trial: NCT00909298
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT03699215
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: continuous perfusion of 0.1 micrograms / kg / min for 24h. If the initial dose is tolerated and a greater hemodynamic effect is needed, the infusion rate can be increased to 0.2 micrograms / kg / min.
Trial: NCT00249899
Drug: Stable statin therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lapaquistat acetate placebo-matching, tablets, orally, once daily and stable statin therapy for up to 24 weeks.
Trial: NCT00583076
Drug: AST-120
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AST-120, 2grams,three times daily for 4 weeks. Responders in the second cohort of patients are eligible to receive AST-120 for up to 52 weeks.
Trial: NCT02352831
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00742404
Drug: pegylated liposomal doxorubicin hydrochloride
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03686085
Drug: Dinoprostone 3 mg
RxNorm normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) inserted by the study nurse 6 hours before IUD insertion.
Trial: NCT03686085
Drug: placebo vaginal tablet
RxNorm normalized name: placebo Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vaginal tablet of placebo inserted by the study nurse 6 hours before IUD insertion.
Trial: NCT01298362
Drug: Aromatase Inhibitors
RxNorm normalized name: Aromatase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04545580
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo for BAY1817080, will be taken twice daily orally as tablet(s)
Trial: NCT04545580
Drug: BAY1817080
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BAY1817080 will be taken twice daily orally as tablet(s)
Trial: NCT01441232
Drug: LX4211
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 mg of LX4211 administered as two 200 mg tablets
Trial: NCT01441232
Drug: Januvia®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Trial: NCT01378585
Drug: DLBS1033
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 490 mg DLBS1033 daily
Trial: NCT01378585
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 x 1 tablet daily
Trial: NCT02109185
Drug: Nasonex® Nasal Spray, 50 μg/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02109185
Drug: Nasonex® Nasal Spray Suspnsn, 50 μg/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02109185
Drug: Placebo Nasal Spray, 50 μL/actuation
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00089401
Drug: isolated perfusion
RxNorm normalized name: ISOLATE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01608945
Drug: Hydrocortisone sodium succinate
RxNorm normalized name: Hydrocortisone Sodium Succinate
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 100mg/day
Trial: NCT02722083
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo tablet, single dose, orally
Trial: NCT03515668
Drug: Placebo Oral Tablet
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with same appearance/taste
Trial: NCT02169427
Drug: OPC
RxNorm normalized name: DOPC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The drug substance of 100 mg OPC was administered as 1 capsule.
Trial: NCT00214201
Drug: Calcineurin inhibitor withdrawal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: stopping tacrolimus or cyclosporine in subjects who received Campath-1H induction therapy
Trial: NCT03944317
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A total of 1500mg Azithromycin tablets taken orally as 500mg daily for three consecutive days starting starting from 16weeks of pregnancy and to be repeated once at least after 4 weeks
Trial: NCT00420771
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo comparator appears identical to active medication and is prescribed with an identical dosing schedule with a maximum dose of 400mg taken three times per day
Trial: NCT00641667
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fentanyl 1-day application transdermal patch releasing the drug at the rate of 12.5 microgram per hour (mcg/hr) to 100 mcg/hr applied once daily, and maintained for 2 days. Dose escalation or reduction is as per Investigator's discretion (maximum applied dose is 300 mcg/hr) up to Day 7 and then dose is fixed for next 3 days that is Day 10 (end of treatment period).
Trial: NCT01041963
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs and spironolactone. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 130/80 mmHg
Trial: NCT01227018
Drug: STA-9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02383212
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03800147
Drug: Mutaflor Suspension (E. coli Nissle 1917)
RxNorm normalized name: Duraflor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inoculation of Mutaflor Suspension (E. coli Nissle 1917)
Trial: NCT02565368
Drug: Duvie Tab. 0.5mg, Glucophage XR Tab. 1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration
Trial: NCT02565368
Drug: CKD-395 0.5/1000mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: single oral administration
Trial: NCT03762317
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with volume similar to clonidine at 12 mcg/kg/d will be given to this arm in addition to oral morphine
Trial: NCT00124436
Drug: alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01090661
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo intravenous (IV) single dose
Trial: NCT01090661
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo subcutaneous (SC) single dose
Trial: NCT04396561
Drug: Paravertebral group (group P):
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In both groups, one reading of mean arterial pressure and heart rate were taken before induction of general anaesthesia and were defined as baseline readings and then were recorded intra-operatively at 15 min intervals.~Additional bolus doses of fentanyl 0.5µg/kg were given when the mean arterial blood pressure or heart rate raised above 20% of baseline levels.